

5th EURO

-UE-BASED



Constant Artificial Intelligence With Artificial Intelligence IPEAN VAL,

5th EUROPEAN VALUE.

SPROCUREMENT CONFERENCE













Join atmenti.com | use code 5506 2451

EUROPEAN VALUE-BASED PROCUREMENT CONFERENCE How would you describe the Consecutive the How would you describe the Consecutive the How would you describe the How would you de BASED PROCUREMENT CONFERENCE

5th EUROPEAN VA







-





Data is crucial for effective decision-making, yet it often remains isolated within departmental silos



80% of the job involves collecting, organising, joining, and cleaning data



Algorithms serve as the foundation for training models, making predictions, and extracting insights from data

MSTAR



Al is the study and implementation of computer-based systems that mimic or perform tasks requiring human intelligence



- The study of how to make programs/computers do things that people do better
- The study of how to make computers solve problems which require data, knowledge, and intelligence
- The exciting new effort to make computers think ... machines with minds
- The automation of activities that we associate with human thinking (e.g., decision-making, learning...)
- The art of creating machines that perform functions that require intelligence
 when performed by people
- The study of mental faculties through the use of computational models
- A field of study that seeks to explain and emulate intelligent behavior in terms of computational processes
- The branch of computer science that is concerned with the automation of intelligent behavior

Thinking machines or machine intelligence

Studying C cognitive faculties

 C_{O}

Problem Solving and Computer Science

Al has been around for some time, but its development has recently accelerated







5th EUROPEAN VALUE-BASED PROCUREMENT CONFERENCE Sth EUROPEAN Applications of All BROCUREMENT CONFERENCE Past, Present, and Future ALUE-BASED PROCUREMENT CONFERENCE

Traditional AI was already impactful in healthcare, but LLMs have significantly expanded its applications



AMSTA

Traditional AI and deep learning faced challenges with extensive training data requirements and limitations to specific problems





LLMs are pre-trained and can greatly speed up data aggregation, synthesis, and analysis on a large scale



ΔΜSTΔR

Advancements in AI, particularly in Generative AI, may speed up value development and assessment



Al will greatly decrease product R&D time, including software engineering, evidence development, and commercialisation





1) McKinsey & Company (June 2023). The economic potential of generative AI – The next productivity frontier 2) McKinsey Center for Government (July 2023). Generative AI and the future of work

Al needs further evolution to become fully accessible for enterprises and organisations









Data modeling, insight development, and multivariate simulations are crucial for speeding up value analysis

Flexible models that can capture high-dimensional data and complex interdependencies

Sth.

Extracting insights from unstructured data like electronic health records

Stakeholder interaction simulations



HEOR: Health Economics and Outcomes Research

SLR: Systematic Literature Review

NMA - Network Meta Analysis

HTA - Health Technology Assessment

Advancing AI enhances systematic literature reviews, improving care quality and healthcare system efficiency



@ 2023

Data from various sources can be extracted, analysed, and visualised for comprehensive evidence evaluation





- Accuracy 85-90%; Sensitivity 95%-97%; Specificity 70%-90%
- The process can be incredibly fast 40,000 abstracts in 10 minutes
- Very detailed data extraction sheets for quality assessment 4////
- PRISMA flow diagram completion

Accurately identify eligible RCTs effortlessly Highly adaptable to different reviews and easy to use



By integrating a custom NLP network graph with GPT, medical technologies can be analysed more comprehensively



Vamstar's proprietary model can compare all medical technologies across multiple dimensions of evidence ALUE-BA **Study Score Publication Score** V VALUE Study specific and based on the study type, size, duration, and other parameters Study specific and based on the journal, availability, SED PROCURENAS funding, and conflict of interest -BASED PROCURF **Market Score** The information from all studies that are available on a certain device are combined and weighted MENT CONFERM to reach a conclusion regarding the clinical Device specific and based on availability, brochure, evidence for the device complications, and other parameters Devices with no clinical evidence will surface in search results but are flagged as sitting outside of the scoring methodology

GPT can assist in Network Meta Analysis (NMA), essential for complex medical conditions with multiple treatment options







Sth EUROPEAN VALUE-BASED PRO Sth EUROPEAN V**ALUE-BASED PRO** Summary and **Key Challenges** MENT CONFERENCE JROPEAN VALUE-BASED PROCUREMENT CONFERENCE

Al can greatly impact value-based approaches, as shown by numerous industry examples

proprietary data can help to advance the technology.



Earlier attempts to use AI for outcome development and measurement were limited by their narrow focus, data demands, and overall effectiveness

Star,

٢

Large language models (LLMs) are more versatile than traditional AI models because they are trained on massive amounts of data and can generate new data instances.

OpenAI has released a series of powerful AI models, but concerns about data privacy persist. Masking

 \mathbb{P}

^`@ □√

Versatile and easily implementable AI is now available, with applications in evidence generation and analysis already in use and more on the horizon

₽

With the right software and processes, we are moving towards a future where outcome-based projects can be completed through natural language compands

Ľ

With new more powerful models and with things like "fine tuning" this will all get even better quickly!





Should we accelerate the adoption of AI in all areas, particularly for evidence generation, development, and analysis, throughout our industry?

EUROPEAN VALUE-BASED



5th EUROPEAN VALUE-BASED PROCUREMENT CONFERENCE Sth EUROPEAN About Vamstar EUROPEAN EUROPEAN EUROPEAN EUROPEAN EUROPEAN EUROPEAN EUROPEAN EUROPEAN EUROPEAN ERECTOR UROPEAN VALUE-BASED PROCUREMENT CONFERENCE

About Vamstar



- Vamstar is the MedTech and Pharmaceutical data and marketplace platform that uses AI to (1) gather and manage tender and non-tender data from over 100 countries, (2) analyse \$780 billion of recurring spending to provide insights, (3) automate commercial and procurement processes, and (4) enhance supply chain resilience through network integration
- We collaborate with public and private buy-and-supply side organisations worldwide, including hospitals, GPOs, and global MedTech/Pharmaceutical companies
- Our cloud-based platform delivers data, analysis, insights, and tools for commercial and procurement teams. The outcome is an interconnected buyer-and-supplier ecosystem
- Vamstar was founded by experienced professionals from various industry sectors, including commercial, sales, strategy, technology, tendering, finance, sourcing, and procurement. Our headquarters is in London, United Kingdom, and we have offices in Germany, India, Netherlands, United Arab Emirates, and the United States





A Sth EUROPEAN VALUE BASED PEAN VALUE BASED Vanstar: Data, Insights, and Tools in One Al Platform Vanstar: Data, Insights, and Tools in One Al Platform REMENT CONFERENCE Q&A 511 VARSTAR VALUE VALUE SED PROCUREMENT ROCUREMENT

vamstar.io customercare@vamstar.io © 2022 VAMSTAR. All rights reserved. No portion of this report may be reproduced, reused, or otherwise distributed in any form without prior written constant, with the exception of any internal client distribution as may be permitted in the license agreement between client and VAMSTAR permission must display VAMSTAR legal notices and attributes of authorship. The information contained herein is from sources considered reliable but its accuracy and completeness are not warranted, nor are the opinions and anaylses which are based upon it, and to the extent permitted by law, VAMSTAR shall not be liable for any errors or omissions or any loss, damage or expense incurred by reliance on information or any statement contained herein. For more information, please contact VAMSTAR at <u>customercare@vamstar.io</u>, +44 (0) 330-133-1383 (from outside North America). All products, company names or other marks appearing in this publication are the trademarks and property of VAMSTAR or their respective owners.